Acrodermatitis Continua Resistant to Etanercept: Therapeutic Challenge and Unfortunate Outcome
June 2008
in “
Journal of the European Academy of Dermatology and Venereology
”
Studysummary This paper discusses a case of acrodermatitis continua that was resistant to treatment with etanercept, highlighting the therapeutic challenges faced, but reports no new research results. Our plain-language summary of this paper — not a Tressless recommendation.
The document described a 47-year-old man with Acrodermatitis continua of Hallopeau (ACH) who did not improve after treatment with etanercept, among other therapies. His condition, characterized by erythema, pustules, and nail loss, progressed to generalized pustular psoriasis, causing significant pain and disability. This case, along with another from Turkey, suggests that genetic and racial factors may affect the response to etanercept in ACH patients. The authors emphasize the need for more research on the effectiveness of biological agents in treating ACH, acknowledging the difficulty due to the rarity of the condition and the reliance on individual case reports for information.
